

**NSAIDs**  
**(Non-selective cox**  
**inhibitors: Aspirin & other**  
**commonly used NSAIDs)**

**DR SHAMS SULEMAN**

# LEARNING OBJECTIVES

- Classify NSAIDs
- Differentiate between nonselective COX inhibitors and selective COX-2 inhibitors based on mechanism of action
- Name the prototype nonselective COX inhibitor
- Describe mechanism of action of Aspirin as antiplatelet, analgesic/antipyretic and as anti inflammatory drug
- Give the dose of Aspirin as antiplatelet, analgesic/antipyretic and as anti inflammatory drug
- Describe clinical uses of NSAIDs

# LEARNING OBJECTIVES .....

- Describe the adverse effects of NSAIDs
- Describe the drug treatment of Aspirin poisoning
- Describe the pharmacokinetics with emphasis on dosage, duration of action and elimination of Diclofenac, Ibuprofen, Indomethacin, Mefenamic acid and Piroxicam in contrast to Aspirin
- Relate pharmacokinetics and pharmacodynamics of NSAIDs to their clinical applications

# Cyclooxygenase enzymes

Arachidonic acid

NSAIDs —| COX-1

COX-2 —| NSAIDs  
COX-2 inhibitors

- Constitutive
- Normal tissue
- Housekeeping functions

- Inducible
- Inflammation
- Pain
- Cancer

PGH<sub>2</sub>

PGE<sub>2</sub>

PGF<sub>2α</sub>

PGD<sub>2</sub>

PGI<sub>2</sub>

TX

**Prostanoids**

(Prostaglandins, thromboxanes)


# FUNCTIONS OF COX


## COX-1


- Constitutively expressed
- Housekeeping functions
- Present in every organ  
stomach, intestine,  
kidney, **platelets**,  
vascular endothelium

## COX-2


- Inducible
- Inflammatory &  
neoplastic sites
- Also present in kidney,  
uterus, ovary, brain,  
small intestine













# PERIPHERAL SENSITIZATION TO PAIN





## C FIBERS

SLOW.  
SENSES DULL,  
LINGERING,  
PAINS.

## A-DELTA FIBERS

FAST.  
SENSES ACUTE,  
PIERCING,  
PAINS.







© 2000 UTHSCH

**Figure 8.1**


**The gate control theory of pain modulation. The gate control theory is based on presynaptic inhibition of pain information produced by mechanical stimulation, and provides the basic rationale for the TENS.**

## Gate Control Hypothesis:

- Interneurons activated by  $A\beta$  fibers act as a gate, controlling primarily the transmission of pain stimuli conveyed by C fibers to higher centers.
- Rubbing the skin near the site of injury to feel better.
- Transcutaneous electrical nerve stimulation (TENS).
- Dorsal column stimulation
- Acupuncture




# Gate-control theory of pain



(a) Unmodulated pain

Central nervous system

Peripheral nervous system




(b) Modulation of pain

# ANALGESICS


- 1) Act at the site of injury and decrease the pain associated with an inflammatory reaction (e.g. NSAIDs)
- 2) Alter nerve conduction (e.g. local anesthetics): block action potentials by blocking Na channels.
- 3) Modify transmission in the dorsal horn (e.g. opioids).
- 4) Affect the central component and the emotional aspects of pain (e.g. opioids, antidepressant).

# WHO Analgesic 'Ladder'





# SITE OF ACTION



# CLASSIFICATION (chemical)

## SALICYLIC ACID DERIVATIVES

- Aspirin
- Sodium salicylate
- Methyl salicylate
- Choline salicylate
- Magnesium salicylate
- Diflunisal
- Benorylate

# CLASSIFICATION (contd.)

## FENAMIC ACID DERIVATIVES

- Mefenamic acid, meclofenamate sodium

## PROPIONIC ACID DERIVATIVES

- Ibuprofen, naproxen, fenbufen, fenoprofen, flurbiprofen, ketoprofen

## ENOLIC ACID DERIVATIVES

- Piroxicam, meloxicam (oxicams); nabumetone

# CLASSIFICATION (contd.)

## PYRAZOLON DERIVATIVES

- phenylbutazone, azapropazone, oxyphenbutazone

## COX 2 SELECTIVE

- Celecoxib, etoricoxib, rolicoxib, lummaricoxib

# CLASSIFICATION (contd.)

## ACETIC ACID DERIVATIVES

- Indomethacin
- Diclofenac
- Etodolac
- Sulindac
- Ketorolac
- Tolmetin

# CLASSIFICATION (contd.)

## PARA-AMINO PHENOL DERIVATIVE


➤ Paracetamol

# General properties in common:

- Organic acids EXCEPT nabumetone
- Well absorbed
- Strongly protein bound
- Highly metabolized
- Renal excretion mainly
- Varying enterohepatic circulation
- Distributed in synovial fluid

# Aspirin (Acetylsalicylic acid; ASA)

- Willow bark- Salicin
- Synthesized in 1853
- Organic acid
- Ester of acetic acid





# HISTORY

- Salicylic acid-natural product, present in the bark of willow and poplar trees
- Active ingredient, isolated by a French pharmacist in the 18<sup>th</sup> century, was **Salicin**, oxidized to Salicylic acid
- In 1828 a Swizz pharmacist, Lowig, distilled **meadowsweet flowers** and got salicylaldehyde
- 1897, a chemist at the Bayer Company produced acetylsalicylic acid
- The name **Aspirin** was coined by adding an **a** for acetyl to **spirin** from the name of the plant (*Spirea ulmaria*) from which salicylic acid was first isolated

# ANTI INFLAMMATORY DRUGS

## PHARMACOKINETICS

- All= weak acids except Nebutomone (ketone)
- Racemic, single (naproxen), non (diclofenac)
- Biotransformation= phase 1 & 2 reactions
- CYT P<sub>450</sub> 2C, CYT P<sub>450</sub> 3A
- Enterohepatic circulation
- Excretion = renal

# Pharmacokinetics

- Rapidly absorbed from stomach and upper small intestine
- Hydrolyzed to acetic acid and salicylate by esterases in tissue and blood
- Bound to albumin
- **ZERO ORDER KINETICS**
- Conjugated in liver and cleared by kidney
- Excretion: 25 % excreted unchanged & 75 % as metabolites in urine ,enhanced by **ALKALINIZATION**
- $t_{1/2}$  15mins but antiplatelet action 8-10 days

# ANTI INFLAMMATORY DRUGS

## PHARMACODYNAMICS

Inhibition of prostaglandins = cyclooxygenase

Reversible acetylation (aspirin= irreversible)

Minor mechanisms


- Inhibition of chemotaxis
- IL 1 down regulation
- Decreased free radicals & superoxides
- Interference with intracellular calcium

# PHARMACODYNAMICS.....

- ✓ NOT Disease Modifying
- ✓ Non selective inhibition = most
- ✓ Aspirin, indomethacin, piroxicam and sulindac = mostly COX 1
- ✓ Ibuprofen, meclofenamate = both equally
- ✓ Celecoxib, Refocoxib, Valdecoxib, melocoxib and etoricoxib = selective COX 2 inhibitors  
same efficacy, gastroprotection , more edema

# Mechanism of Action

- Inhibits both COX-I and COX-II
  - Anti-inflammatory
  - Analgesic
  - Antipyretic
- Aspirin irreversibly inhibits platelet COX
  - Anti-platelet effect (lasts 8-10 days)



## ANTI-INFLAMMATORY (in large doses)

- Rheumatoid arthritis
- Ac rheumatic fever along ē benzyl penicillin

## ANTI-PYRETIC

- Lowers fever

## AS ANTI-PLATELET (in low doses 75 – 100mg/day)

- For transient ischemic attacks & cerebrovascular stroke
- Prophylaxis of unstable angina, MI
- Thrombosis after coronary artery by pass grafting

# Anti –inflammatory effect

Inhibits PG synthesis at the periphery

- Inhibit migration of polymorphs and macrophages at site of inflammation
- Inhibition of granulocytes adherence to damaged vasculature
- Stabilizes lysosomes
- Interferes with chemical mediators of kalikrein system





# Antipyretic


- Aspirin reduces only elevated temperature & has no effect on normal temperature
- Aspirin resets the temperature regulating centre to normal by inhibition of PGE<sub>2</sub> synthesis
- Blocks the action of IL-1 released from macrophages by action of bacterial endotoxins / inflammation
- Vasodilatation of superficial blood vessels causing inc. dissipation of heat

# Antiplatelet effect


- Aspirin in small doses decreases platelet aggregation by suppressing the synthesis of thromboxane  $A_2$
- It irreversibly acetylates the COX
- Effect lasts for 8 – 10 days till new platelets are regenerated
- High doses suppress prostacyclins also & platelet inhibitory effect is lost







**Figure 1.** Aspirin mechanism of action -- acetylation of cyclooxygenase (COX). Aspirin acetylates a serine (Ser) residue of COX and irreversibly inactivates COX-1. In the case of COX-2, aspirin "turns off" its ability to generate prostaglandins, but "switches on" its capacity to produce novel protective lipid mediators.



Phospholipids

Phospholipases

Platelets

Arachidonic acid

X

X

X

COX-1

NSAIDS

Tromboxane A2  
(TXA2)

Platelet aggregation induction  
vasoconstriction

Low-dose aspirin  
Selective COX-1 inhibition  
Full antiplatelet effect

High-dose aspirin  
Non-selective COX-1/COX-2 inhibition  
¿Diminished antiplatelet effect?

Phospholipases

Endothelial cells

Arachidonic acid

NSAIDS  
Coxibs

X


X

COX-2


Prostacyclin  
(PGI2)

Platelet aggregation inhibition  
vasodilation

# Platelet COX-1



# After aspirin



- The aspirin induced suppression of thromboxane A<sub>2</sub> synthetase and the resulting suppression of platelet aggregation last for the life of the anucleate platelet approximately 7 to 10 days. Thus aspirin induced prolongation of B.T last for 5-7 day



# ANTIPLATELET DRUGS

These are the drugs which interfere with platelet function and useful in the prophylaxis of thromboembolic disorders.

Clinically important antiplatelet drugs are:

Aspirin

Clopidogrel


Dipyridamole

Abciximab

Ticlopidine

Tirofiban

Eptifibatide



**Key:** TXA<sub>2</sub> = thromboxane; GP = glycoprotein; ADP = adenosine diphosphate; CAMP = cyclic adenosine monophosphate

# Analgesic Effect

- Reduces mild to moderate pain of varying cause (pain of musculoskeletal structures) relieved better than of visceral origin
- Mainly acts at **periphery** at nociceptive level so effective in pain associated with inflammation (pain of muscular, vascular & dental origin, postpartum states, arthritis & bursitis is relieved)

# Effect on GIT

- a. Vomiting-- Stimulation of CTZ
- b. Dose related gastric ulceration & hemorrhage, due to inhibition of protective PGI<sub>2</sub>
  - Ischemia of gastric mucosa
  - Increased gastric acid secretion & pepsin
  - Inhibition of gastric mucous secretion

# Other effects

- **Uricosuric action:** dependent on dose
- In high doses above 4 gms
- **CVS:**
  - a) In low doses--- cardioprotective effect
  - b) In large doses--- increased circulating volume and peripheral vasodilatation
  - c) In toxic doses--- depress circulation directly & by central Vasomotor paralysis
- **Respiration:**
  - a) In therapeutic doses, Increased depth of resp.
  - b) In large doses-Compensated resp. alkalosis
  - c) In toxic doses - Uncompensated resp. acidosis

# ANTI INFLAMMATORY DRUGS

USES;      most NSAIDS are effective

- ❖ Rheumatoid arthritis/Rheumatic heart disease
- ❖ Ischemic heart disease
- ❖ Inflammatory bowel disease/reactive arthritis
- ❖ Ankylosing spondylitis, Psoriatic arthritis, Gout
- ❖ Trauma, post operative, dental diseases
- ❖ Menstrual disorders/ dysmenorrhoea
- ❖ Patent ductus arteriosus, carcinoma colon

# INDOMETHACIN & OTHERS....

## Additional uses (Indomethacin)

- PDA
- Juvenile RA/ post laminectomy syndrome
- Pleurisy
- Nephrotic syndrome/Diabetes insipidus
- Post arthroplasty (heterotropic calcification)
- Corneal abrasions (ophthalmic drops)
- Gingivitis (oral gel)

# ASPIRIN (ASA)


- ASA = Pka, 3.5 vs 3.0 (salicylic acid)
- Esterases = 15 minutes ---acetic acid and salicylates--- stomach, upper GIT
- Avoid = concomitant ibuprofen, probenecid
- Can use acetaminophen
- Albumin bound, Elimination  $t_{1/2}$  = 3-5 hours
- Salicylism, respiratory alkalosis, metabolic acidosis--- urinary alkalization, dialysis



# DOSAGE

- Prevention of stroke and MI 75-150 mg inhibits platelet aggregation
- Analgesic effect 300 mg 6 hourly to max of 4 gm daily
- Osteoarthritis and rheumatoid arthritis, 900 mg every 6 hourly
- Acute rheumatic fever, 0.9-1.2 g every 4 hourly max of 8 gm

# Dose dependent effects of Aspirin



# ANTI INFLAMMATORY DRUGS

## ADVERSE EFFECTS

- CNS= headache, tinnitus, dizziness
- CVS= edema, hypertension, CCF
- GIT= Dyspepsia, bleeding, nausea, vomiting
- Hematological= thrombocytopenia, aplastic anemia(rare), neutropenia
- Renal= Hyperkalemia, proteinuria, azotemia
- Hepatitis, asthma, rashes, SJ syndrome

# ADVERSE EFFECTS OF ASPIRIN

## 1. Gastric upsets:

- Erosive gastritis & Gastric ulceration
  - Hematemesis
  - Melena
  - Occult Blood In stool
- Dyspepsia and heart burn
- Nausea & vomiting

## 2) Effects on CNS

### Salicylism:

- (In large doses): Tinnitus, deafness, dimness of vision, dizziness, ataxia, mental confusion, vertigo, nausea & vomiting, sweating, thirst
- (In Toxic Doses): Hyperpyrexia, CV collapse, convulsions, ketosis, coma

## 3) Related to Kidney:

### Analgesic Nephropathy

## 4) **Reye syndrome**

## 4. **Respiratory system**

- Hyperventilation
- Compensated respiratory alkalosis (high doses)
- Uncompensated acidosis (toxic doses)

## 5. **Blood**

- Hypoprothrombinaemia
- Increase bleeding tendency

## 6. **Allergic / Hypersensitivity Reactions**

- Bronchospasm
- Urticaria
- Rhinitis
- Hay Fever

# IBUPROFEN

- Phenylpropionic acid derivative
- Anti inflammatory effect start at 2400 mg/dl (equivalent to 4gm aspirin anti-inflammatory effect)
- Lower dose has analgesic effect
- Closure of patent ductus arteriosus in preterm infants
- Less decrease in urine output, less fluid retention
- Decreases antiplatelet effect of aspirin
- Oral I/V, topical

# INDOMETHACIN

- Indole derivative
- Potent non-selective COX inhibitor and may also inhibit phospholipase A and C
- Reduce neutrophil migration and decrease T-cell and B-cell proliferation
- Effective in joint pain, swelling & tenderness
- Gout, arthritis
- Accelerate closure of patent ductus arteriosus
- Pancreatitis, frontal headache
- $t_{1/2}$  prolonged by probenecid



# DICLOFENAC SODIUM

- Phenylacetic acid derivative
- Combinations are available (+ misoprostol)
- 150 mg/d impair renal blood flow & GFR
- GI ulceration less frequent
- Elevation of serum aminotransferases

**Preparations:** eye drops, topical gel, suppository

**Dose:** 50-75mg qid

# OTHERS....

## **KETOPROFEN**

- Both lipoyxygenase and cyclooxygenase enzymes are inhibited
- Intravenous and oral

## **KETOROLAC**

- Analgesic without much anti inflammatory properties
- May obviate the need for opioids

# OTHERS....

- MEFANAMIC ACID
- Inhibits both cyclooxygenase and phospholipase A
- DICLOFENAC SODIUM
- Avoid with Aspirin
- Hepatotoxic : like Sulindac

# DRUG INTERACTIONS

- Concomitant NSAID's & low dose aspirin
- ACE inhibitors
- Warfarin
- Sulfonylurea hypoglycemics
- Methotrexate

# Management of aspirin/salicylate overdose toxicity/poisoning (salicylism)

1. Gastric lavage
2. Activated charcoal
3. Correct fluid, electrolyte & acid base balance
4. Maintain high urine out put
5. Keep airway patent
6. ↓ Body temp. by cold sponging
7. Vit. K I/V to correct hypopthrombinemia
8. Diazepam I/V for convulsions
9. Promote excretion of salicylates by  $\text{NaHCO}_3$  I/V to alkalinize urine ,maintain pH at 8.0
10. Hemodialysis in pts. with severe acidosis & coma

1. Choose the drug which alter surface receptors on platelet membrane to inhibit aggregation
  - a. Dipyridamole
  - b. Ticlopidine
  - c. Aspirin
  - d. Heparin
  
2. Following drug increase cyclic AMP in platelets and inhibit their aggregation without altering levels of thromboxane A<sub>2</sub> or prostacycline.
  - a. Aspirin
  - b. Dipyridamole
  - c. Abciximab
  - d. Sulfnipyrazone
  
3. Aspirin prolongs bleeding time by inhibiting the synthesis of
  - a. Clotting factor in liver
  - b. Cyclic AMP in platelet
  - c. Prostacycline in vascular endothelium
  - d. Thromboxane A<sub>2</sub> in platelet

# New drug classes in development for pain and inflammation

- NO-linked NSAIDs
- Dual LOX/COX inhibitors
- iNOS inhibitors
- PAR2 receptor antagonists
- Selective opioids
- Cannabinoid receptor antagonists
- Calcium channel blockers
- Vanilloid receptor antagonists
- *N*-acetylcholine receptor antagonists
- Glycine antagonists
- Neurokinin antagonists
- Calcitonin gene-related antagonists
- COX-3 inhibitors

# REFERENCES

**Basic & Clinical Pharmacology, 14<sup>th</sup> Edition:  
Bertram G. Katzung**

**Katzung & Trevor's Pharmacolog: Examination  
& Board Review, 12<sup>th</sup> Edition**

**Lippincott illustrated review Pharmacology: 6<sup>th</sup>  
Edition**



Email address for queries on the topic

[drshams11@hotmail.com](mailto:drshams11@hotmail.com)